Table 2.
Risk of diabetes complications associated with ADT use, among men diagnosed with localized prostate cancer, who received primary treatment with RP or RT
| Post-diagnostic diabetes complications | Event rate per 1,000 person years in ADT users | Event rate per 1,000 person years in ADT non-users | Unadjusted HR (95% CIs) | Adjusted HRa (95% CIs) |
|---|---|---|---|---|
| Any complication | 249.3 | 231.9 | 1.26 (1.17–1.37) | 1.12 (1.03–1.23) |
| Diabetic cataracts | 153 | 136.6 | 1.27 (1.16–1.38) | 0.98 (0.90–1.08) |
| Diabetic neuropathy | 75.8 | 76.9 | 1.23 (1.11–1.36) | 1.14 (1.02–1.28) |
| Diabetic retinopathy | 12.7 | 24.8 | 0.63 (0.52–0.77) | 1.17 (0.92–1.47) |
| Diabetic amputation | 4.3 | 1.9 | 2.20 (1.45–3.35) | 2.06 (1.28–3.31) |
ADT androgen deprivation therapy, HR hazard ratio
a
Adjusted in a multivariable analysis using Cox proportional hazards models for ethnicity, health plan, AUA risk group, comorbidity according to the Elixhauser index, prostate cancer treatment (RP or RT), age at diagnosis (years), and diabetes severity. Ever use of ADT modeled as time varying